{"artifact":{"id":"open_question-therapeutics-4f08ff22","artifact_type":"open_question","entity_ids":"[\"therapeutics\"]","title":"Which specific branches of the kynurenine pathway are most therapeutically relevant for targeted intervention in distinct neurological, neurodegenerative, and neuropsychiatric disorders?","quality_score":0.7,"created_by":"open_question_miner_papers","provenance_chain":"[]","content_hash":"c1f7c1da1f0ea1f6bfa6e1654ba08dd8e256db80177b6ffab341c2cf20f1255b","metadata":{"status":"open","_origin":{"url":null,"type":"external","tracked_at":"2026-04-28T06:15:39.059385"},"field_tag":"therapeutics","source_id":"34205235","source_doi":"10.1038/s41416-019-0664-6","source_kind":"paper","question_hash":"4f08ff220bb06242","question_text":"Which specific branches of the kynurenine pathway are most therapeutically relevant for targeted intervention in distinct neurological, neurodegenerative, and neuropsychiatric disorders?","importance_elo":1500,"_schema_version":1,"source_paper_id":"paper-df37f9271a6b","evidence_summary":"therapeutic implications for development of selected and efficacious treatment strategies","tractability_score":0.5,"potential_impact_score":0.9,"is_answerable_in_principle":true},"created_at":"2026-04-27T23:15:39.059450-07:00","updated_at":"2026-04-27T23:15:39.059450-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"external","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"e7cef053-89dc-483b-a778-fd6883be84bf","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"open_question_miner_papers"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"open_question-therapeutics-4f08ff22","is_canonical":true,"supersede_chain":["open_question-therapeutics-4f08ff22"]}